AI-powered analysis for predicting optimal immune checkpoint inhibitor combinations based on tumor microenvironment, biomarkers, and molecular profiling.
The Immune Checkpoint Combination Agent analyzes tumor molecular profiles to predict optimal immune checkpoint inhibitor (ICI) combinations. It integrates TME characterization, checkpoint expression, resistance mechanisms, and clinical evidence for rational immunotherapy combination design.
Checkpoint Expression Profiling: Quantify expression of PD-1, PD-L1, CTLA-4, TIGIT, LAG-3, TIM-3, and others.
TME Characterization: Classify tumors as "hot" (inflamed), "excluded", or "cold" (desert) for combination rationale.
: Identify primary and acquired resistance patterns.
Combination Prediction: ML models predicting response to specific checkpoint combinations.
Synergy Scoring: Evaluate potential synergies based on mechanism of action overlap.
Clinical Evidence Integration: Match combinations to published efficacy data.
| Target | Approved Agents | Mechanism | Combination Rationale |
|---|---|---|---|
| PD-1 | Pembrolizumab, Nivolumab | Block T-cell inhibition | Backbone therapy |
| PD-L1 | Atezolizumab, Durvalumab | Block tumor immune evasion | Alternative backbone |
| CTLA-4 | Ipilimumab, Tremelimumab | Enhance T-cell priming | Non-redundant to PD-1 |
| LAG-3 | Relatlimab | Block exhausted T-cells | PD-1 refractory |
| TIGIT | Tiragolumab | Block NK/T suppression | NK cell engagement |
| TIM-3 | Multiple in trials | Terminal exhaustion | Highly exhausted TME |
Input: Tumor RNA-seq, IHC markers, TMB/MSI status, clinical data.
Checkpoint Profiling: Quantify checkpoint ligand/receptor expression.
TME Classification: Determine immune infiltration pattern.
Resistance Analysis: Identify potential resistance mechanisms.
Combination Scoring: Rank combinations by predicted efficacy.
Evidence Matching: Link to clinical trial data.
Output: Ranked combinations, rationale, supporting evidence, trial matches.
User: "Recommend optimal checkpoint inhibitor combination for this melanoma patient based on their tumor profile."
Agent Action:
python3 Skills/Immunology_Vaccines/Immune_Checkpoint_Combination_Agent/ici_combination.py \
--rnaseq tumor_expression.tsv \
--ihc pd-l1_tps_60.json \
--mutations tumor_mutations.maf \
--tmb 12.5 \
--msi stable \
--tumor_type melanoma \
--prior_treatment pembrolizumab \
--output ici_recommendations.json
Inflamed ("Hot") Tumors:
Excluded Tumors:
Desert ("Cold") Tumors:
| Mechanism | Biomarkers | Combination Strategy |
|---|---|---|
| Alternative checkpoints | LAG-3+, TIGIT+, TIM-3+ | Add second checkpoint |
| WNT/β-catenin | CTNNB1 mutations | Poor ICI candidate |
| IFN signaling loss | JAK1/2, B2M mutations | Limited benefit |
| MHC loss | HLA-A/B/C loss | NK-engaging therapies |
| T-cell exclusion | TGF-β high | TGF-β inhibitor combination |
Response Prediction:
Synergy Prediction:
| Combination | Indication | Key Trial | Benefit |
|---|---|---|---|
| Nivo + Ipi | Melanoma | CheckMate-067 | OS improvement |
| Nivo + Rela | Melanoma | RELATIVITY-047 | PFS improvement |
| Atezo + Tira | NSCLC | CITYSCAPE | PFS improvement (PD-L1 high) |
| Durva + Treme | HCC | HIMALAYA | OS improvement |
AI Group - Biomedical AI Platform